Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a Healthcare company (Biotechnology) with a market capitalization of $479M. The Maz Rating grades it against the other companies in its sector.
Fennec Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.58, Fennec Pharmaceuticals Inc. trades at 582.9x trailing earnings, 7.1x sales and 9.5x book value, with an EV/EBITDA of 161.9. Over the last twelve months it generated about $68M of revenue and $822552 of net income. It runs a gross margin of 94.1%, an operating margin of 5.6% and a net margin of 3.1%. It shows return on equity of 4.9%, return on invested capital of 4.2% and a free cash flow yield of 0.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.11. Over the past 52 weeks the share price ranged from $5.65 to $13.64, with a beta of 1.21.
Fennec Pharmaceuticals Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Fennec Pharmaceuticals Inc. (FENC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.8% / 30% · Interest income / Revenue 1.63% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.8% / 33% · Receivables / Mkt Cap (36m) 6.25% / 49% · Interest income / Revenue 1.63% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.8% / 33.33% · Receivables / Mkt Cap (24m) 6.25% / 33.33% · Interest income / Revenue 1.63% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 55.3% / 33.33% · Receivables / Avg Assets (4Q) 29.5% / 33.33% · Interest income / Revenue 1.63% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 58.3% / 33.33% · (Cash+Recv) / Total Assets 86.7% / 33.33% · Interest income / Revenue 1.63% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Fennec Pharmaceuticals Inc. (FENC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Fennec Pharmaceuticals Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.63% of each dividend: Fennec Pharmaceuticals Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.